Sort By:
Date
Title
Category:

Why should you engage early with regulators and HTA bodies?

NDA’s Dr Mira Pavlovic-Ganascia and Claes Buxfeldt provide insight on what the expected outcomes of constructively engaging with regulators and HTA bodies could be.

| Articles, Health Technology Assessment, Homepage News, Library News, White Papers

The state of the Swedish orphan pipeline

Business Sweden, together with SwedenBIO, have outlined the current state of Swedish orphan development in a new report. It describes a vibrant drug development landscape that is reflective of the global move towards orphan development and the strong emphasis on oncology.

| Articles, Homepage News, se

In memoriam - Dr Eric Abadie

We were all greatly saddened to learn of the recent passing of our colleague and friend Dr Eric Abadie.

| Homepage News, Regulatory Advisory Board

4 ways that HTA will change under the new European regulation

In this white paper NDA's CEO, Johan Strömquist, discusses four ways that Health Technology Assessments will change under the new proposed European regulation.

| Articles, Health Technology Assessment, Homepage News, Library News, White Papers

Optimizing Value - Regulatory and Market Access Considerations

Welcome to NDA's seminar on 21st May 08:30-13:00 in Solna, Sweden on Optimizing Value - Regulatory and Market Access Considerations.

| Community News, Health Technology Assessment, Homepage News, Social News

Webinar - Is an Early Development Strategy Really Needed?

Join us on 16th May at 15:00 BST, 16:00 CEST, 10:00 EDT for this engaging webinar with Dr Niamh Kinsella, Biologics Expert, VP, Early Stage Development.

| Homepage News, Library News

Observations of a market access expert

An insightful interview with NDA’s Claes Buxfeldt, HTA Director, entitled “Observations of a market access expert” featured in Aprils edition of Pharmafocus.

| Articles, Health Technology Assessment, Homepage News

Interactions with Agencies During Drug Development

Welcome to NDA’s free Lunch seminar on Tuesday 30th April 12:00- 14:00 in the UK on Interactions with Agencies During Drug Development.

| Community News, Events & Presentations, High-stakes Meeting Preparation, Homepage News, Social News

Meet the NDA experts in March

| Homepage News

Interactions with Agencies During Drug Development

Welcome to NDA’s free Breakfast seminar on Wednesday 20th March 08:30- 10:00 on Interactions with Agencies During Drug Development.

| Community News, Events & Presentations, High-stakes Meeting Preparation, Homepage News, Social News

Passionate about solutions for patients with rare diseases

Rare Disease Day is NDA Groups' opportunity to show that we care passionately about this work and about getting treatments to the patients affected and to promote the vital work that is going on in this space by so many passionate patients, physicians and scientists.

| Community News, Homepage News, Services News, Social News

Effective presentation of immunogenicity related data in regulatory dossiers

NDAs Paul Chamberlain provides practical advice about how to present immunogenicity-related information in regulatory dossiers in the latest publication of Bioanalysis.

| Articles, Homepage News, Library News, Translational Science

Immunogenicity for investigational biopharmaceutical products – Start with the goal in mind

Welcome to NDA’s free Breakfast seminar in Munich, Germany, on Thursday 14th March 09:00- 10:30 on Immunogenicity for investigational biopharmaceutical products – Start with the goal in mind.

| Community News, Events & Presentations, Homepage News, Social News

Seasoned drug development professional Kim Forbes-McKean PhD to lead NDA Group’s US expansion

Kim Forbes-McKean PhD, joins NDA Group from a distinguished career spanning more than 30 years of leading research and development activities for large pharma, as well as small biotech companies.

| Community News, Homepage News, Services News

Free Webinar - Brexit Impact: Are you ready?

Join us on Thursday 14th February for this engaging webinar with Thomas Lönngren, Strategic Advisor and Dr Brian Edwards, Principal Consultant about Brexit impact.

| Homepage News, Library News, Presentations and Infographics